Actually, Genmab is trying and if they succeed SGEN gets to participate.
Somewhat ironic Genmab selects the ADC tech from SGEN instead of Medarex's linker tech.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr